Well done team PTX! Two CR in relapsed AML patients is an outstanding result! However would like to know ORR of the 13.
With regard to the mentioned peculiar toxicities, it is a known fact that majority of frontline chemo drugs alone are hard & toxic on the liver (Transamine, elevation of hepatic enzymes into bloodstream) Cytarabine is no exception as per: -
https://www.ncbi.nlm.nih.gov/pubmed/2178634
Also mentioned is relatively frequent, but does not represent therapeutic problem.
Goodness me appendicitis...seriously...I've suffered that after a decent bout of the flu let alone full on chemotherapy
..
Which is why the team have chosen to slightly lower Cytarabine dose to find the optimum combination that suits a broader target.
I do not see this as a PTX200 toxicity issue, PTX200 has already proven to be low toxicity at current dosing levels, just a matter of finding that sweet spot in combination therapy.
I bet if you asked the 4 CR & many other PR & SD patients in PXT200 trials what they think of the drug? I'm sure they all would call it a miracle that has saved or bettered their quality of life, whereby nothing else on the market can achieve this result.
C'mon ASX get behind this company, it will be the ride of a life time! (Sorry Psych could not resist)
